Navidea Biopharmaceuticals Inc. | |
Stock Exchange | NYSE |
EPS |
$1.33 |
Market Cap |
$10.8 M |
Shares Outstanding |
18.06 M |
Public Float |
152.4 M |
Navidea Biopharmaceuticals Inc. | |
Stock Exchange | Frankfurt Stock Exchange |
EPS |
- |
Market Cap |
- |
Shares Outstanding |
163.62 M |
Public Float |
156.27 M |
Address |
4995 Bradenton Avenue Dublin Ohio 43017 United States |
Employees | - |
Website | http://www.navidea.com |
Updated | 07/08/2019 |
Navidea Biopharmaceuticals, Inc. engages in the development and commercialization of precision immunodiagnostic agents and immunotherapeutic. It is developing multiple precision-targeted products based on their manocept platform to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making, targeted treatment and, ultimately, patient care. The company operates through the following segments: Diagnostics, Therapeutics, and Corporate. |